Log In
BCIQ
Print this Print this
 

MEDI2542

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionNeutralising antibody that binds to ticagrelor and AR-C124910XX, the ticagrelor active metabolite
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Hematology (unspecified)
Indication DetailsReverse the antiplatelet effects of ticagrelor
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today